Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition.Partridge, J.R., Choy, R.M., Silva-Garcia, A., Yu, C., Li, Z., Sham, H., Metcalf, B.
(2019) J Struct Biol 206: 170-182
- PubMed: 30876891
- DOI: 10.1016/j.jsb.2019.03.001
- Primary Citation of Related Structures:
6BFP, 6O1G, 6O1S
- PubMed Abstract:
- Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors.
Li, Z., Partridge, J., Silva-Garcia, A., Rademacher, P., Betz, A., Xu, Q., Sham, H., Hu, Y., Shan, Y., Liu, B., Zhang, Y., Shi, H., Xu, Q., Ma, X., Zhang, L.
(2017) ACS Med Chem Lett 8: 185
Plasma kallikrein (pKal) is a serine protease responsible for cleaving high-molecular-weight kininogen to produce the pro-inflammatory peptide, bradykinin. Unregulated pKal activity can lead to hereditary angioedema (HAE) following excess bradykinin release ...
Plasma kallikrein (pKal) is a serine protease responsible for cleaving high-molecular-weight kininogen to produce the pro-inflammatory peptide, bradykinin. Unregulated pKal activity can lead to hereditary angioedema (HAE) following excess bradykinin release. HAE attacks can lead to a compromised airway that can be life threatening. As there are limited agents for prophylaxis of HAE attacks, there is a high unmet need for a therapeutic agent for regulating pKal with a high degree of specificity. Here we present crystal structures of both full-length and the protease domain of pKal, bound to two very distinct classes of small-molecule inhibitors: compound 1, and BCX4161. Both inhibitors demonstrate low nM inhibitory potency for pKal and varying specificity for related serine proteases. Compound 1 utilizes a surprising mode of interaction and upon binding results in a rearrangement of the binding pocket. Co-crystal structures of pKal describes why this class of small-molecule inhibitor is potent. Lack of conservation in surrounding residues explains the ∼10,000-fold specificity over structurally similar proteases, as shown by in vitro protease inhibition data. Structural information, combined with biochemical and enzymatic analyses, provides a novel scaffold for the design of targeted oral small molecule inhibitors of pKal for treatment of HAE and other diseases resulting from unregulated plasma kallikrein activity.
Global Blood Therapeutics, South San Francisco, CA 94080, United States.